设为首页 加入收藏

TOP

ZYTIGA 250 mg tabletsAbiraterone Acetate(五)
2013-07-03 20:33:43 来源: 作者: 【 】 浏览:7051次 评论:0
ith ZYTIGA: hypokalaemia 3%; urinary tract infection 2%; peripheral oedema, alanine aminotransferase increased, hypertension, cardiac failure and atrial fibrillation, 1% each. CTCAE (version 3.0) Grade 3 hypertriglyceridaemia and angina pectoris occurred in < 1% of patients. CTCAE (version 3.0) Grade 4 peripheral oedema, hypokalaemia, urinary tract infection, and cardiac failure occurred in < 1% of patients.

Description of selected adverse reactions

Cardiovascular reactions

The phase 3 study excluded patients with uncontrolled hypertension, clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association Class III or IV heart disease or cardiac ejection fraction measurement of < 50%. All patients enrolled (both active and placebo-treated patients) were concomitantly treated with androgen deprivation therapy, predominantly with the use of LHRH agonists, which has been associated with diabetes, myocardial infarction, cerebrovascular accident and sudden cardiac death. Cardiovascular adverse reactions in the phase 3 study occurred in 11% of patients who received ZYTIGA and in 7% of patients who received placebo.

Hepatotoxicity

Hepatotoxicity with elevated ALT, aspartate transaminase (AST) and total bilirubin has been reported in patients treated with ZYTIGA. Across all clinical studies, liver function test elevations (ALT or AST increases of > 5 x ULN or bilirubin increases > 1.5 x ULN) were reported in approximately 2% of patients who received ZYTIGA, typically during the first 3 months after starting treatment. In the phase 3 clinical study, patients whose baseline ALT or AST were elevated were more likely to experience liver function test elevations than those beginning with normal values. When elevations of either ALT or AST > 5 x ULN, or elevations in bilirubin > 3 x ULN were observed, ZYTIGA was withheld or discontinued. In two instances marked increases in liver function tests occurred (see section 4.4). These two patients with normal baseline hepatic function, experienced ALT or AST elevations 15 to 40 x ULN and bilirubin elevations 2 to 6 x ULN. Upon discontinuation of ZYTIGA, both patients had normalisation of their liver function tests and one patient was re-treated without recurrence of the elevations.

In clinical trials, the risk for hepatotoxicity was mitigated by exclusion of patients with active or symptomatic hepatitis or baseline ALT and AST  2.5 x ULN in the absence of liver metastases and > 5 x ULN if liver metastases were present. Abnormal liver function tests developing in patients participating in clinical trials were vigorously managed by requiring treatment interruption and permitting re-treatment only after return of liver function tests to the patient's baseline (see section 4.2). Patients with elevations of ALT or AST > 20 x ULN were not re-treated. The safety of re-treatment in such patients is unknown. The mechanism for hepatotoxicity is not understood.

4.9 Overdose

 There have been no reports of overdose during clinical studies.

There is no specific antidote. In the event of an overdose, administration should be withheld and general supportive measures undertaken, including monitoring for arrhythmias, hypokalaemia and for signs and symptoms of fluid retention. Liver function also should be assessed.

5. PHARMACOLOG

以下是“全球医药”详细资料
Tags: 责任编辑:admin
首页 上一页 2 3 4 5 6 7 8 下一页 尾页 5/10/10
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇ELIGARD 22.5 mg, powder and sol.. 下一篇没有了

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位